2024-512515-45-01
招募中
1 期
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
Theras Inc.16 个研究点 分布在 2 个国家目标入组 45 人开始时间: 2026年3月23日最近更新:
概览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Theras Inc.
- 入组人数
- 45
- 试验地点
- 16
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Contact point
Scientific
Theras Inc.
研究点 (16)
Loading locations...
相似试验
招募中
1 期
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)2024-512089-32-00ADC Therapeutics SA121
招募中
1 期
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications2023-506227-29-00AbbVie Deutschland GmbH & Co. KG60
尚未招募
1 期
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors2024-516870-31-00Merck Sharp & Dohme LLC14
已完成
1 期
A Phase I, Open-Label Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose2022-500921-34-00Achieve Life Sciences Inc.56
尚未招募
1/2 期
A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.2024-512954-96-00Cantex Pharmaceuticals Inc.32